Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Ovarian Neoplasms 4Lung Neoplasms 4Breast Neoplasms 4Fallopian Tube Neoplasms 3Prostatic Neoplasms 2Brenner Tumor 2Head and Neck Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Brain Neoplasms 1Advanced Non-small Cell Lung Cancer 1Advanced Colorectal Cancer 1

Interventions

Paclitaxel 114Carboplatin 114Cisplatin 45Topotecan 43Gemcitabine 31Cyclophosphamide 31Docetaxel 28liposomal doxorubicin 27Bevacizumab 27Filgrastim 20pembrolizumab 19Peripheral Blood Stem Cell Transplantation 18Taxes 15Drug Therapy 15sargramostim 12Hyperthermic Intraperitoneal Chemotherapy 12olaparib 11Chemotherapy, Adjuvant 10Surgical Procedures, Operative 9Etoposide 9oregovomab 8mirvetuximab soravtansine 8Nivolumab 8Amifostine 8Therapeutics 7Melphalan 7Erlotinib Hydrochloride 7rucaparib 6aldesleukin 6Oxaliplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Ovarian Epithelial × paclitaxel poliglumex × Clear all
NCT00017017 2013-05-30

CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡